...

Full product catalog is available after authentication authenticate here!

Free US shipping for orders above $200

Contact Us
Semaglutide

This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.

Semaglutide : Metabolic & Weight Support

Semaglutide is a GLP-1 receptor agonist drug approved by the FDA in June 2021 for the treatment of adult obesity. In January 2023, it was also approved for the chronic weight management of adolescents aged 12 and above. This drug achieves weight loss by delaying gastric emptying, suppressing appetite, and regulating insulin secretion.

Specifications Without Label Price With Label Price
5mg × 10 vials $55.00 $65.00
10mg × 10 vials $105.00 $115.00
15mg × 10 vials $135.00 $145.00
20mg × 10 vials $160.00 $170.00
30mg × 10 vials $180.00 $190.00

 

Contact Us
  • Ships Today if ordered within 10 hrs 27 min.
  • Free international delivery within 1-3 business days on orders over $600, with a tracking number provided.
  • Our Support Team

HPLS
Testing

Endotoxin
Assay

TYMC
Test

TYMC
Test

Heavy Metal
Screening

Characteristics

Property Details
Molecular Formula C187H291N45O59
Molecular Weight 4113.58 g/mol
CAS Number 910463-68-2
Appearance White to off-white Powder
Composition Lyophilized powder – requires reconstitution

 

Mimics GLP-1: The drug activates GLP-1 receptors, which helps regulate insulin and glucagon production.

Slows Gastric Emptying: This keeps food in the stomach longer, helping control hunger and prevent rapid sugar absorption.

Reduces Appetite: Patients often experience decreased cravings and smaller portion sizes.

Benefits of Semaglutide

Blood Sugar Control:
Semaglutide stimulates insulin release when blood sugar levels are high, helping prevent spikes and maintain stable glucose levels.

Weight Management:
By reducing appetite and promoting a feeling of fullness, Semaglutide can assist with weight loss, making it an option for people struggling with obesity or overweight-related conditions.

Cardiovascular Health:
Clinical studies suggest that Semaglutide may reduce the risk of cardiovascular events like heart attack and stroke in patients with type 2 diabetes.

Potential Side Effects
Common side effects include:

  • Nausea and vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • Headache
  • Severe side effects are rare but can include pancreatitis or kidney issues.

Clinical Trials

Adult trial: In the phase III clinical trial targeting obese patients, after 68 weeks of medication, the average weight loss was up to 15%-18%.
Teenager trial: The expanded indication clinical trial showed that the drug was as safe as in adults in the teenage population and had a significant weight loss effect.

References

  1. Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci. 2022.
  2. Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023.
  3. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021.
  4. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
  5. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022.
  6. Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022.
  7. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
  8. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022.
  9. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvásy-Szabó A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
  10. Dandona P, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes. N Engl J Med. 2023.
  11. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017.
  12. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022.
  13. Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res. 2022.
  14. Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021.
  15. McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023.
  16. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring). 2023.
  17. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021.
  18. Niu S, Chen S, Chen X, Ren Q, Yue L, Pan X, Zhao H, Li Z, Chen X. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022.
  19. Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023.

Disclaimer

All product is sold solely for scientific research purposes. Researchers are responsible for ensuring compliance with local regulations and institutional guidelines. Keep out of reach of children and unauthorized personnel.

Your Reliable Source for High-Quality Research Peptides

1688pharmacy is more than just a trusted supplier of research peptides. We are committed to scientific advancement, dedicated to providing the highest quality pharmaceutical-grade compounds that empower researchers and clients to achieve their goals.

Unparalleled Quality

Our proprietary processes and meticulous sourcing of premium materials ensure that every peptide we offer meets the most stringent pharmaceutical standards with verified 99% purity.

Independently Verified

Every peptide undergoes rigorous third-party laboratory testing using advanced techniques like HPLC, LC-MS, and NMR. Complete Certificates of Analysis available for transparency and verification.

Fast Shipping & Support

We provide expedited worldwide shipping with reliable tracking and discreet packaging. Our dedicated customer support team assists with orders, storage guidelines, and product inquiries promptly.